Skip to main content
LigaChem Biosciences Inc. logo

LigaChem Biosciences Inc. — Investor Relations & Filings

Ticker · 141080 ISIN · KR7141080002 KO Professional, scientific and technical activities
Open in API
Filings indexed 295 across all filing types
Latest filing 2019-03-29 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 141080

About LigaChem Biosciences Inc.

https://ligachembio.com/

LigaChem Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative medicines. Leveraging its core expertise in medicinal chemistry, the company focuses on developing Antibody-Drug Conjugates (ADCs), immuno-oncology drugs, and small molecules. A key asset is its proprietary, next-generation ADC platform technology, engineered to overcome the limitations of conventional ADC technologies. The company's pipeline includes multiple programs targeting oncology, as well as other therapeutic areas such as antibiotics and anti-fibrotics. LigaChem Biosciences actively pursues global drug development through strategic partnerships, including co-development and licensing agreements with international pharmaceutical companies.

Recent filings

Filing Released Lang Actions
사업보고서 (2018.12)
Interim / Quarterly Report Classification · 95% confidence The document is a 'Consolidated Audit Report' (연결감사보고서) for LegoChem Biosciences for the fiscal year ending December 31, 2018. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. This is a comprehensive annual financial report for a period, which fits the definition of an Interim/Quarterly Report (IR) in the context of this classification system, as it contains full financial statements and audit results for the fiscal year. FY 2018
2019-03-29 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details changes in share ownership by major shareholders and special related parties, including specific transaction dates, methods (e.g., stock option exercises, market trades), and funding sources. This document type is specifically used for reporting significant changes in shareholding thresholds and does not fit into the other categories like 10-K, ER, or RNS. In the context of the provided filing categories, this is classified as a Major Shareholding Notification.
2019-03-28 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (정기주주총회결과). It details the outcomes of various agenda items, including the approval of financial statements, dividend decisions, and the election of directors and auditors. This falls directly under the category of Declaration of Voting Results & Voting Rights Announcements.
2019-03-26 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서). This is a standard regulatory filing in South Korea (DART system) used when a company director or major shareholder reports changes in their personal shareholdings, such as stock option exercises or insider trades. This falls under the 'Director's Dealing' category.
2019-03-26 Korean
투자판단관련주요경영사항(항체-약물 복합체(ADC) 원천기술 이전계약(라이선스) 체결)
M&A Activity Classification · 95% confidence The document is a regulatory filing from LegoChem Biosciences regarding a major business event: the signing of a technology transfer (licensing) agreement for their ADC platform with Millenium Pharmaceuticals. This is a specific announcement of a material business transaction, which falls under the category of general regulatory announcements or material event disclosures. Since it does not fit into specific categories like M&A (which usually refers to corporate takeovers/mergers) or capital raising, it is best classified as a general regulatory filing.
2019-03-22 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It provides the audit opinion (적정/Unqualified), financial highlights (assets, liabilities, equity, profit/loss), and details regarding the external auditor. While it contains financial data, it is a summary announcement of the audit results rather than the full 10-K annual report or a standalone audit report document. Given the structure and the nature of the disclosure, it fits the 'Report Publication Announcement' (RPA) category as it announces the completion and submission of the audit report. FY 2018
2019-03-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.